封面
市場調查報告書
商品編碼
1578213

全球急性激動和攻擊性治療市場研究報告 - 2024 年至 2032 年行業分析、規模、佔有率、成長、趨勢和預測

Global Acute Agitation And Aggression Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: | 出版商: Value Market Research | 英文 231 Pages | 商品交期: 最快1-2個工作天內

價格

全球急性激動和攻擊性治療市場的需求預計將從 2023 年的 48.5 億美元增至 2032 年的近 80.2 億美元,2024-2032 年研究期間的複合年成長率為 5.75%。

急性激動是指伴隨或不伴隨異常運動活動的內在緊張或不安狀態。而急性攻擊性則意味著有可能自殘或傷害他人的行為表現。急性激動和攻擊性治療只不過是為治癒患者的激動和攻擊性而提供的醫療護理。一般來說,個體的急性躁動和攻擊性是由於憂鬱、躁鬱症、酒精依賴、荷爾蒙失衡、自閉症、壓力和神經系統疾病等原因引起的。急性躁動和攻擊性治療可以幫助恢復平靜感。

市場動態

由於心理疾病中激動和攻擊診斷的增加、心理疾病經濟負擔的增加以及傳播意識的組織的形成,全球急性激動和攻擊治療市場越來越受歡迎。改變精神病患者對激動和攻擊行為診斷的態度以及對治療認知的提高可能會推動全球急性激動和攻擊行為治療市場的成長。此外,針對急性躁動和攻擊性的新療法的研究和開發預計將推動市場成長。精神疾病的增加、老年人口失智症發病率的增加、患者躁動的激增以及抗精神病藥物處方的增加正在推動未來幾年急性躁動和攻擊性治療市場的成長。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外,這些工具也對全球急性激動和攻擊性治療市場的各個細分市場進行了包容性評估。急性激動和攻擊性治療行業的成長和趨勢為這項研究提供了整體方法。

市場區隔

急性激動和攻擊性治療市場報告的這一部分提供了有關國家和區域層面細分市場的詳細資料,從而幫助策略家確定相應產品或服務的目標人口統計數據以及即將到來的機會。

依治療方法

  • 行為方法
  • 環境介入
  • 藥理學方法(藥物)(勞拉西泮、氯丙嗪、喹硫平、氟哌利多、奧氮平、齊拉西酮等)

按指示

  • 精神分裂症
  • 失智
  • 躁鬱症
  • 沮喪
  • 藥物引起的躁動和攻擊性
  • 酒精戒斷
  • 其他

依給藥途徑

  • 口服
  • 肌肉注射
  • 其他

按最終用戶

  • 醫院及門診手術中心
  • 精神科護理設施
  • 其他
  • 區域分析

本節涵蓋區域前景,重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲的全球急性激動和攻擊性治療市場報告市場當前和未來的需求。此外,該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。急性激動和攻擊性治療市場的主要參與者包括禮來公司、輝瑞公司、大塚控股、葛蘭素史克、H. Lundbeck A/S、強生公司、梯瓦製藥工業有限公司、Amneal Pharmaceuticals LLC、Sun Pharmaceutical Industries有限公司、F. Hoffmann-La Roche Ltd、Bausch Health Companies Inc.、Apotex Inc.、Aurobindo Pharma。本節包含競爭格局的整體視圖,包括各種策略發展,例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求,請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

目錄

第1章:前言

  • 報告說明
    • 客觀的
    • 目標受眾
    • 獨特的銷售主張 (USP) 和產品
  • 研究範圍
  • 研究方法
    • 市場研究過程
    • 市場研究方法論

第 2 章:執行摘要

  • 市場亮點
  • 全球市場概況

第 3 章:急性激動與攻擊行為治療 - 產業分析

  • 簡介 - 市場動態
  • 市場促進因素
  • 市場限制
  • 機會
  • 產業動態
  • 波特五力分析
  • 市場吸引力分析
    • 依處理法進行市場吸引力分析
    • 按指標進行的市場吸引力分析
    • 按給藥途徑進行的市場吸引力分析
    • 最終用戶的市場吸引力分析
    • 市場吸引力分析:按地區

第 4 章:價值鏈分析

  • 價值鏈分析
  • 原料分析
    • 原料清單
    • 原料廠商清單
    • 主要原物料價格走勢
  • 潛在買家名單
  • 行銷管道
    • 直效行銷
    • 間接行銷
    • 行銷通路發展趨勢

第 5 章:全球急性激動與攻擊行為治療市場分析:依治療方法分類

  • 依治療方法概述
  • 依處理方法進行歷史和預測資料分析
  • 行為方法
  • 環境介入
  • 藥理學方法(藥物)(勞拉西泮、氯丙嗪、喹硫平、氟哌利多、奧氮平、齊拉西酮等)

第 6 章:全球急性激動與攻擊行為治療市場分析:依適應症分類

  • 按指示概述
  • 按指示進行歷史和預測資料分析
  • 精神分裂症
  • 失智
  • 躁鬱症
  • 沮喪
  • 藥物引起的躁動和攻擊性
  • 酒精戒斷
  • 其他

第 7 章:全球急性激動與攻擊行為治療市場分析:依給藥途徑

  • 依給藥途徑概述
  • 按給藥途徑進行歷史和預測資料分析
  • 口服
  • 肌肉注射
  • 其他

第 8 章:全球急性躁動與攻擊性治療市場分析:依最終使用者分類

  • 最終用戶概述
  • 最終用戶的歷史和預測數據分析
  • 醫院及門診手術中心
  • 精神科護理設施
  • 其他

第 9 章:全球急性躁動與攻擊性治療市場分析:依地理位置

  • 區域展望
  • 介紹
  • 北美銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 北美按細分市場銷售分析
    • 北美按國家銷售分析
    • 美國銷售分析
    • 加拿大銷售分析
    • 墨西哥銷售分析
  • 歐洲銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 歐洲按細分市場銷售分析
    • 歐洲按國家銷售分析
    • 英國銷售分析
    • 法國銷售分析
    • 德國銷售分析
    • 義大利銷售分析
    • 俄羅斯銷售分析
    • 歐洲其他地區銷售分析
  • 亞太地區銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 亞太地區按細分市場銷售分析
    • 亞太地區按國家銷售分析
    • 中國銷售分析
    • 印度銷售分析
    • 日本銷售分析
    • 韓國銷售分析
    • 澳洲銷售分析
    • 東南亞銷售分析
    • 亞太地區其他地區銷售分析
  • 拉丁美洲銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 拉丁美洲按細分市場銷售分析
    • 拉丁美洲按國家銷售分析
    • 巴西銷售分析
    • 阿根廷銷售分析
    • 秘魯銷售分析
    • 智利銷售分析
    • 拉丁美洲其他地區銷售分析
  • 中東和非洲銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 中東和非洲按細分市場銷售分析
    • 中東和非洲按國家銷售分析
    • 沙烏地阿拉伯銷售分析
    • 阿拉伯聯合大公國銷售分析
    • 以色列銷售分析
    • 南非銷售分析
    • 中東其他地區和非洲銷售分析

第 10 章:急性激動與攻擊行為治療公司的競爭格局

  • 急性躁動和攻擊性治療市場競爭
  • 夥伴關係/協作/協議
  • 併購
  • 新產品發布
  • 其他發展

第 11 章:公司簡介

  • 頂級公司市佔率分析
  • 市場集中度
  • Eli Lilly And Company
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Pfizer Inc.
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Otsuka Holdings
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • GlaxoSmithKline
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • H. Lundbeck A/S
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Johnson & Johnson
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Teva Pharmaceutical Industries Ltd.
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Amneal Pharmaceuticals LLC
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Sun Pharmaceutical Industries Ltd.
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • F. Hoffmann-La Roche Ltd
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Bausch Health Companies Inc.
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Apotex Inc.
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Aurobindo Pharma
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態

註 - 在公司概況中,財務詳細資訊和最新發展視情況而定,或對私人公司而言可能不包括在內

Product Code: VMR11218412

The global demand for Acute Agitation And Aggression Treatment Market is presumed to reach the market size of nearly USD 8.02 Billion by 2032 from USD 4.85 Billion in 2023 with a CAGR of 5.75% under the study period 2024-2032.

Acute Agitation refers to the state of inner tension or unease with or without abnormal motor activity. While acute aggression signifies a behavioural expression with the potential to self-harm or harm others. Acute agitation and aggressive treatment are nothing but the medical care given to a patient to get cured of agitation and aggression. Generally, acute agitation and aggression are caused in an individual due to reasons like depression, bipolar disorder, alcohol dependency, hormonal imbalances, autism, stress, and neurological disorders. Acute agitation and aggression treatment can help in restoring the sense of calm.

MARKET DYNAMICS

The global acute agitation and aggression treatment market is gaining popularity owing to the rise in the agitation and aggression diagnosis in psychological illnesses, the increase in the economic burden of psychological illness, and the formation of an organization to spread awareness. Altering attitudes toward agitation and aggression diagnosis among mentally ill patients and an increase in awareness about treatments are likely to fuel the global acute agitation and aggression treatment market growth. Additionally, research and development of novel treatments for acute agitation and aggression are expected to drive market growth. The rise in mental illness, increase in dementia incidences among the geriatric population, the rush in agitation in patients, and an increase in prescriptions of anti-psychotics are boosting the growth of the acute agitation and aggression treatment market in the forthcoming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Acute Agitation And Aggression Treatment. The growth and trends of Acute Agitation And Aggression Treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Acute Agitation And Aggression Treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Treatment Approach

  • Behavioral Approaches
  • Environmental Interventions
  • Pharmacologic Approaches (Drugs) (Lorazepam, Chlorpromazine, Quetiapine, Droperidol, Olanzapine, Ziprasidone, Others)

By Indication

  • Schizophrenia
  • Dementia
  • Bipolar Disorder
  • Depression
  • Drug-induced Agitation and Aggression
  • Alcohol Withdrawal
  • Others

By Route of Administration

  • Oral
  • Intramuscular
  • Others

By End User

  • Hospitals & Ambulatory Surgical Centers
  • Psychiatric Care Facilities
  • Others
  • Regional Analysis

This section covers the regional outlook, which accentuates current and future demand for the Global Acute Agitation And Aggression Treatment Market Report market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Acute Agitation And Aggression Treatment market include Eli Lilly And Company, Pfizer Inc., Otsuka Holdings, GlaxoSmithKline, H. Lundbeck A/S, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Apotex Inc., Aurobindo Pharma. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. ACUTE AGITATION AND AGGRESSION TREATMENT - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Treatment Approach
    • 3.7.2 Market Attractiveness Analysis By Indication
    • 3.7.3 Market Attractiveness Analysis By Route of Administration
    • 3.7.4 Market Attractiveness Analysis By End User
    • 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET ANALYSIS BY TREATMENT APPROACH

  • 5.1. Overview By Treatment Approach
  • 5.2. Historical and Forecast Data Analysis By Treatment Approach
  • 5.3. Behavioral Approaches Historic and Forecast Sales By Regions
  • 5.4. Environmental Interventions Historic and Forecast Sales By Regions
  • 5.5. Pharmacologic Approaches (Drugs) (Lorazepam, Chlorpromazine, Quetiapine, Droperidol, Olanzapine, Ziprasidone, Others) Historic and Forecast Sales By Regions

6. GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET ANALYSIS BY INDICATION

  • 6.1. Overview By Indication
  • 6.2. Historical and Forecast Data Analysis By Indication
  • 6.3. Schizophrenia Historic and Forecast Sales By Regions
  • 6.4. Dementia Historic and Forecast Sales By Regions
  • 6.5. Bipolar Disorder Historic and Forecast Sales By Regions
  • 6.6. Depression Historic and Forecast Sales By Regions
  • 6.7. Drug-induced Agitation and Aggression Historic and Forecast Sales By Regions
  • 6.8. Alcohol Withdrawal Historic and Forecast Sales By Regions
  • 6.9. Others Historic and Forecast Sales By Regions

7. GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

  • 7.1. Overview By Route of Administration
  • 7.2. Historical and Forecast Data Analysis By Route of Administration
  • 7.3. Oral Historic and Forecast Sales By Regions
  • 7.4. Intramuscular Historic and Forecast Sales By Regions
  • 7.5. Others Historic and Forecast Sales By Regions

8. GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET ANALYSIS BY END USER

  • 8.1. Overview By End User
  • 8.2. Historical and Forecast Data Analysis By End User
  • 8.3. Hospitals & Ambulatory Surgical Centers Historic and Forecast Sales By Regions
  • 8.4. Psychiatric Care Facilities Historic and Forecast Sales By Regions
  • 8.5. Others Historic and Forecast Sales By Regions

9. GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET ANALYSIS BY GEOGRAPHY

  • 9.1. Regional Outlook
  • 9.2. Introduction
  • 9.3. North America Sales Analysis
    • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.3.2 North America By Segment Sales Analysis
    • 9.3.3 North America By Country Sales Analysis
    • 9.3.4 United States Sales Analysis
    • 9.3.5 Canada Sales Analysis
    • 9.3.6 Mexico Sales Analysis
  • 9.4. Europe Sales Analysis
    • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.4.2 Europe By Segment Sales Analysis
    • 9.4.3 Europe By Country Sales Analysis
    • 9.4.4 United Kingdom Sales Analysis
    • 9.4.5 France Sales Analysis
    • 9.4.6 Germany Sales Analysis
    • 9.4.7 Italy Sales Analysis
    • 9.4.8 Russia Sales Analysis
    • 9.4.9 Rest Of Europe Sales Analysis
  • 9.5. Asia Pacific Sales Analysis
    • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.5.2 Asia Pacific By Segment Sales Analysis
    • 9.5.3 Asia Pacific By Country Sales Analysis
    • 9.5.4 China Sales Analysis
    • 9.5.5 India Sales Analysis
    • 9.5.6 Japan Sales Analysis
    • 9.5.7 South Korea Sales Analysis
    • 9.5.8 Australia Sales Analysis
    • 9.5.9 South East Asia Sales Analysis
    • 9.5.10 Rest Of Asia Pacific Sales Analysis
  • 9.6. Latin America Sales Analysis
    • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.6.2 Latin America By Segment Sales Analysis
    • 9.6.3 Latin America By Country Sales Analysis
    • 9.6.4 Brazil Sales Analysis
    • 9.6.5 Argentina Sales Analysis
    • 9.6.6 Peru Sales Analysis
    • 9.6.7 Chile Sales Analysis
    • 9.6.8 Rest of Latin America Sales Analysis
  • 9.7. Middle East & Africa Sales Analysis
    • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.7.2 Middle East & Africa By Segment Sales Analysis
    • 9.7.3 Middle East & Africa By Country Sales Analysis
    • 9.7.4 Saudi Arabia Sales Analysis
    • 9.7.5 UAE Sales Analysis
    • 9.7.6 Israel Sales Analysis
    • 9.7.7 South Africa Sales Analysis
    • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE ACUTE AGITATION AND AGGRESSION TREATMENT COMPANIES

  • 10.1. Acute Agitation And Aggression Treatment Market Competition
  • 10.2. Partnership/Collaboration/Agreement
  • 10.3. Merger And Acquisitions
  • 10.4. New Product Launch
  • 10.5. Other Developments

11. COMPANY PROFILES OF ACUTE AGITATION AND AGGRESSION TREATMENT INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Market Concentration Rate
  • 11.3. Eli Lilly And Company
    • 11.3.1 Company Overview
    • 11.3.2 Company Revenue
    • 11.3.3 Products
    • 11.3.4 Recent Developments
  • 11.4. Pfizer Inc.
    • 11.4.1 Company Overview
    • 11.4.2 Company Revenue
    • 11.4.3 Products
    • 11.4.4 Recent Developments
  • 11.5. Otsuka Holdings
    • 11.5.1 Company Overview
    • 11.5.2 Company Revenue
    • 11.5.3 Products
    • 11.5.4 Recent Developments
  • 11.6. GlaxoSmithKline
    • 11.6.1 Company Overview
    • 11.6.2 Company Revenue
    • 11.6.3 Products
    • 11.6.4 Recent Developments
  • 11.7. H. Lundbeck A/S
    • 11.7.1 Company Overview
    • 11.7.2 Company Revenue
    • 11.7.3 Products
    • 11.7.4 Recent Developments
  • 11.8. Johnson & Johnson
    • 11.8.1 Company Overview
    • 11.8.2 Company Revenue
    • 11.8.3 Products
    • 11.8.4 Recent Developments
  • 11.9. Teva Pharmaceutical Industries Ltd.
    • 11.9.1 Company Overview
    • 11.9.2 Company Revenue
    • 11.9.3 Products
    • 11.9.4 Recent Developments
  • 11.10. Amneal Pharmaceuticals LLC
    • 11.10.1 Company Overview
    • 11.10.2 Company Revenue
    • 11.10.3 Products
    • 11.10.4 Recent Developments
  • 11.11. Sun Pharmaceutical Industries Ltd.
    • 11.11.1 Company Overview
    • 11.11.2 Company Revenue
    • 11.11.3 Products
    • 11.11.4 Recent Developments
  • 11.12. F. Hoffmann-La Roche Ltd
    • 11.12.1 Company Overview
    • 11.12.2 Company Revenue
    • 11.12.3 Products
    • 11.12.4 Recent Developments
  • 11.13. Bausch Health Companies Inc.
    • 11.13.1 Company Overview
    • 11.13.2 Company Revenue
    • 11.13.3 Products
    • 11.13.4 Recent Developments
  • 11.14. Apotex Inc.
    • 11.14.1 Company Overview
    • 11.14.2 Company Revenue
    • 11.14.3 Products
    • 11.14.4 Recent Developments
  • 11.15. Aurobindo Pharma
    • 11.15.1 Company Overview
    • 11.15.2 Company Revenue
    • 11.15.3 Products
    • 11.15.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Treatment Approach (USD MN)
  • Behavioral Approaches Market Sales By Geography (USD MN)
  • Environmental Interventions Market Sales By Geography (USD MN)
  • Pharmacologic Approaches (Drugs) (Lorazepam, Chlorpromazine, Quetiapine, Droperidol, Olanzapine, Ziprasidone, Others) Market Sales By Geography (USD MN)
  • Analysis By Indication (USD MN)
  • Schizophrenia Market Sales By Geography (USD MN)
  • Dementia Market Sales By Geography (USD MN)
  • Bipolar Disorder Market Sales By Geography (USD MN)
  • Depression Market Sales By Geography (USD MN)
  • Drug-induced Agitation and Aggression Market Sales By Geography (USD MN)
  • Alcohol Withdrawal Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Analysis By Route of Administration (USD MN)
  • Oral Market Sales By Geography (USD MN)
  • Intramuscular Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Analysis By End User (USD MN)
  • Hospitals & Ambulatory Surgical Centers Market Sales By Geography (USD MN)
  • Psychiatric Care Facilities Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Acute Agitation And Aggression Treatment Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Acute Agitation And Aggression Treatment Report
  • Market Research Process
  • Market Research Methodology
  • Global Acute Agitation And Aggression Treatment Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Treatment Approach
  • Market Attractiveness Analysis By Indication
  • Market Attractiveness Analysis By Route of Administration
  • Market Attractiveness Analysis By End User
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Treatment Approach (USD MN)
  • Behavioral Approaches Market Sales By Geography (USD MN)
  • Environmental Interventions Market Sales By Geography (USD MN)
  • Pharmacologic Approaches (Drugs) (Lorazepam, Chlorpromazine, Quetiapine, Droperidol, Olanzapine, Ziprasidone, Others) Market Sales By Geography (USD MN)
  • Global Market Analysis By Indication (USD MN)
  • Schizophrenia Market Sales By Geography (USD MN)
  • Dementia Market Sales By Geography (USD MN)
  • Bipolar Disorder Market Sales By Geography (USD MN)
  • Depression Market Sales By Geography (USD MN)
  • Drug-induced Agitation and Aggression Market Sales By Geography (USD MN)
  • Alcohol Withdrawal Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Analysis By Route of Administration (USD MN)
  • Oral Market Sales By Geography (USD MN)
  • Intramuscular Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Analysis By End User (USD MN)
  • Hospitals & Ambulatory Surgical Centers Market Sales By Geography (USD MN)
  • Psychiatric Care Facilities Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.